Ann: Court approves convening of scheme meeting, page-9

"The AUD $502.4M (arguably small?) valuation..."

Well BMS are paying up to US$3.6b for just 35% of Nektar's drug, so vla are super cheap compared to that.

I'm giving it a few more weeks for a $2.25 to $2.50 offer to come through. Not sure it will, but I think it makes sense for BMS - even if it's to stop Merck getting hold of CAVATAK.

https://www.ft.com/content/00033a08-119c-11e8-8cb6-b9ccc4c4dbbb